Skip to main content

Table 1 Background and demographic characteristics of patients

From: Efficacy of empagliflozin as adjunctive therapy to citalopram in major depressive disorder: a randomized double-blind, placebo-controlled clinical trial

 

Number (percentage) / average (standard deviation)

Chi2 /t test

P value

 

Group A

N (%)

Group B

N (%)

Total

Gender

Female

23(53.5)

20(46.5)

43(100.0)

0.401

0.527

Male

22(46.8)

25(53.2)

47(100.0)

Job

Housewife

12(41.4)

17(58.6)

29(100.0)

6.387

0.270

Tradesman

6 (60)

4 (40)

10(100.0)

Employee

3(42.9

4(57.1)

7(100.0)

Worker

7(36.8)

12(63.2)

19(100.0)

Unemployed

16(66.7)

8(33.3)

24(100.0)

Retired

1(100.0)

0(0.0)

1(100.0)

Education

Under-Diploma

19(52.77)

17(47.22)

(100.0)36

1.035

0.793

High school Diploma

17(44.73)

21(55.26)

38(100.0)

Academic Degree

9(56.25)

7(43.75)

16(100.0)

Marital

Single

14(50.0)

14(50.0)

28(100.0)

2.675

0.445

Married

21(44.7)

26(57.3)

47(100.0)

Widow

6(75.0)

2(25.0)

8(100.0)

Divorce

4(57.1)

3(42.9)

7(100)

Smoking

Positive

24(57.1)

18(42.9)

42(100.0)

1.607

0.205

Negative

21(43.8)

27(56.3)

48(100.0)

History of Substance Use

Positive

13(54.2)

11(45.8)

24(100.0)

0227

0.634

Negative

32(48.5)

34(51.5)

66(100.0)

Family History of Depression

Positive

21(55.3)

17(44.7)

38(100.0)

0.729

0.393

Negative

24(46.2)

28(53.8)

52(100.0)

History of Suicide

Positive

12(52.17)

11(47.82)

23(100.0)

0.058

0.809

Negative

33(49.25)

34(50.74)

67(100.0)

History of Psychiatric Admission

Positive

21(48.84)

22(51.16)

43(100.0)

0.045

0.833

Negative

24(51.06)

23(48.94)

47(100.0)

Age (years)

34.58(± 8.29)

35.82(± 7.45)

35.20(± 7.87)

(F = 0.574)

0.451

  1. *Group A: Empagliflozin + Citalopram, Group B: Placebo + Citalopram